Antibacterial dressing composition and medical gynecological protection pad

Abstract

The invention provides an antibacterial dressing composition and a medical gynecological protection pad, and belongs to the technical field of medical dressings. The composition is prepared from 70 to 90 parts of water, 8 to 10 parts of polyethylene glycol, 4 to 6 parts of glycerol, 0.3 to 0.7 part of carbomer, 0.06 to 0.15 part of L-cysteine, 4 to 8 parts of chitosan quaternary ammonium salt, 0.3 to 0.8 part of panthenol, 0.4 to 0.7 part of tocopheryl acetate, 0.2 to 0.4 part of sodium hyaluronate, 0.1 to 0.3 part of chlorhexidine digluconate, 3 to 4 parts of polyvinylpyrrolidone, 1 to 5 parts of sodium alginate, 0.1 to 0.3 part of polysorbate, 0.6 to 0.9 part of luteoloside, 0.1 to 0.2 part of quercetin and 0.05 to 0.2 part of sophocarpidine. Chitosan quaternary ammonium salt and chlorhexidine digluconate are used as bactericidal components, quercetin and sophocarpidine are added to serve as bacteriostatic agents, and the bactericidal components, active components such as panthenol, tocopheryl acetate and galuteolin and a film-forming agent form a dispersion system. The antibacterial facial mask has remarkable antibacterial property, and has the effects of resisting inflammation, preserving moisture, promoting tissue repair and the like. The gynecological protection pad acts on the surface of vulva inflammation, and the exact treatment effect can be achieved.

Description

Technical Field

[0001] This invention relates to the field of medical dressing technology, specifically to an antibacterial dressing composition and a medical gynecological pad. Background Technology

[0002] Medical dressings are specialized materials used in the medical field to cover wounds or damaged skin. Their main functions include isolating external contaminants, absorbing exudate, maintaining a moist wound environment, promoting healing, and reducing the risk of infection. They are categorized into traditional types (such as gauze and cotton pads) and functional types (such as hydrocolloid and foam dressings) based on their materials and applications, and are widely used in postoperative care, burns, and chronic ulcers. For wounds and mucous membranes, dressings act as both a physical barrier and provide absorption and moisture retention. Some functional dressings also offer pain relief and adjunctive treatment benefits. Dressings prevent bacteria, dust, and other contaminants from contacting the wound, thus reducing the incidence of infection; they balance exudate absorption with wound moisture, preventing excessive dryness or fluid accumulation, and accelerating cell migration; some dressings contain a gel or adhesive layer, which reduces tearing damage to newly formed tissue during dressing changes; and some dressings (such as those containing silver ions or chitosan) have antibacterial, anti-inflammatory, or angiogenesis-promoting effects.

[0003] Gynecological dressings are medical materials used for the care of the female vulva, vagina, or postoperative wounds. Their main functions are to promote healing, reduce infection, and relieve discomfort. They are suitable for postoperative recovery, inflammation care, or daily cleaning and maintenance. They mainly include liquid dressings, gel dressings, and foam dressings. Liquid dressings are mostly spray or rinse-off types, containing ingredients such as chitosan and hyaluronic acid to form a protective film and reduce redness and swelling. Foam dressings are highly absorbent and are often used in cases of significant postoperative exudation. Gel dressings are suitable for dry or slightly damaged skin, providing a moist environment and relieving itching.

[0004] Vulvitis is an inflammatory reaction of the skin and mucous membranes of the female vulva. Common symptoms include itching, redness, swelling, pain, or abnormal discharge. Vulvitis is mostly caused by microbial infection, with bacteria (such as streptococci and staphylococci), fungi (such as Candida), and viruses (such as HPV) being the main pathogens. The vagina, in particular, is easily exposed to the outside world, making it susceptible to infection due to flora imbalance or poor hygiene. Currently, the treatment of vulvitis mainly relies on medication, such as topical miconazole nitrate and oral fluconazole for fungal infections, and oral metronidazole for bacterial infections. While functional gynecological dressings have some antibacterial properties, their antibacterial efficacy is weak and insufficient to cure vulvitis. Furthermore, their administration methods are inconvenient, which to some extent limits the application of liquid dressings in the treatment of gynecological diseases. Summary of the Invention

[0005] The present invention aims to address the technical deficiencies of the prior art by providing an antibacterial dressing composition to solve the technical problem of weak antibacterial properties in conventional gynecological dressings.

[0006] Another technical problem to be solved by the present invention is: how to develop an antibacterial dressing composition that has a definite therapeutic effect on vulvitis.

[0007] Meanwhile, the present invention provides a medical gynecological pad containing the above-mentioned antibacterial dressing composition to solve the technical problem of inconvenient drug administration when liquid dressings are applied to the vulva.

[0008] To achieve the above technical objectives, the present invention adopts the following technical solution: An antibacterial dressing composition comprising the following components in parts by weight: 70-90 parts water, 8-10 parts polyethylene glycol, 4-6 parts glycerin, 0.3-0.7 parts carbomer, 0.06-0.15 parts L-cysteine, 4-8 parts chitosan quaternary ammonium salt, 0.3-0.8 parts panthenol, 0.4-0.7 parts tocopheryl acetate, 0.2-0.4 parts sodium hyaluronate, 0.1-0.3 parts chlorhexidine digluconate, 3-4 parts polyvinylpyrrolidone, 1-5 parts sodium alginate, 0.1-0.3 parts polysorbate, 0.6-0.9 parts luteolin, 0.1-0.2 parts quercetin, and 0.05-0.2 parts matrine.

[0009] Preferably, the antibacterial dressing composition further includes 0.8 to 1.7 parts by weight of xanthan gum.

[0010] Preferably, the antibacterial dressing composition further includes 0.03 to 0.08 parts by weight of epidermal growth factor (EGF).

[0011] Preferably, the antibacterial dressing composition further includes 0.06 to 0.15 parts by weight of silk fibroin.

[0012] Preferably, the antibacterial dressing composition further includes 0.5 to 0.8 parts by weight of baicalin.

[0013] Preferably, the antibacterial dressing composition comprises the following components in parts by weight: 75-85 parts water, 8.8-9.4 parts polyethylene glycol, 4.5-5 parts glycerin, 0.4-0.6 parts carbomer, 0.08-0.12 parts L-cysteine, 5-7 parts chitosan quaternary ammonium salt, 0.4-0.6 parts panthenol, 0.5-0.65 parts tocopheryl acetate, 0.26-0.33 parts sodium hyaluronate, 0.25-0.3 parts chlorhexidine digluconate, 3.4-3.7 parts polyvinylpyrrolidone, 2.2-3.9 parts sodium alginate, 0.15-0.24 parts polysorbate, 0.8-0.85 parts luteolin, 0.12-0.16 parts quercetin, and 0.13-0.17 parts matrine.

[0014] Preferably, the antibacterial dressing composition comprises the following components in parts by weight: 80 parts water, 9.1 parts polyethylene glycol, 4.8 parts glycerin, 0.53 parts carbomer, 0.11 parts L-cysteine, 6.2 parts chitosan quaternary ammonium salt, 0.55 parts panthenol, 0.62 parts tocopheryl acetate, 0.31 parts sodium hyaluronate, 0.29 parts chlorhexidine digluconate, 3.6 parts polyvinylpyrrolidone, 3.4 parts sodium alginate, 0.2 parts polysorbate, 0.82 parts luteolin, 0.15 parts quercetin, and 0.17 parts matrine.

[0015] Preferably, the antibacterial dressing composition comprises the following components in parts by weight: 80 parts water, 9.1 parts polyethylene glycol, 4.8 parts glycerin, 0.53 parts carbomer, 0.11 parts L-cysteine, 6.2 parts chitosan quaternary ammonium salt, 0.55 parts panthenol, 0.62 parts tocopheryl acetate, 0.31 parts sodium hyaluronate, 0.29 parts chlorhexidine digluconate, 3.6 parts polyvinylpyrrolidone, 3.4 parts sodium alginate, 0.2 parts polysorbate, 0.82 parts luteolin, 0.15 parts quercetin, 0.17 parts matrine, 1.1 parts xanthan gum, 0.06 parts epidermal growth factor (EGF), 0.13 parts silk fibroin, and 0.52 parts baicalin.

[0016] Based on the above technical solutions, the present invention further provides a medical gynecological pad containing the above-mentioned antibacterial dressing composition.

[0017] Preferably, the antibacterial dressing composition is sprayed onto the contact surface of the medical gynecological pad that comes into contact with the human body.

[0018] In the above technical solutions, water is the main solvent in the liquid dressing of this invention, used to dissolve and disperse the various active ingredients, ensuring their uniform distribution and ease of application to the skin surface. Simultaneously, water directly provides immediate moisturizing effects, helping to maintain a moist environment for the mucous membrane, preventing dryness, and promoting mucous membrane stability and barrier repair. Polyethylene glycol plays a moisturizing and film-forming role in this invention, maintaining a moist environment, reducing the risk of infection, and decreasing inflammatory exudation. Glycerin is used to maintain adequate moisture in the lesion, which is beneficial for promoting cell migration and epithelial regeneration, while also soothing irritation and improving the comfort of the dressing in contact with the vulva. Carbomer absorbs wound exudate, forming a transparent film layer, providing a moist environment, and accelerating epithelial cell migration and tissue repair. L-cysteine ​​has antioxidant properties, promotes protein synthesis, and improves the repair of inflammatory damage. Chitosan quaternary ammonium salt is a derivative obtained through chemical modification of chitosan, possessing both the biocompatibility of chitosan and the antibacterial activity of quaternary ammonium salts, playing an antibacterial, bacteriostatic, tissue repair promoting, film-forming, and moisturizing role in this invention.

[0019] Panthenol exerts its anti-inflammatory and soothing effects by inhibiting histamine release and inflammatory factors such as interleukins, while simultaneously accelerating fibroblast proliferation and collagen synthesis, thus shortening wound healing time. Tocopheryl acetate, a synthetic derivative of vitamin E, enhances chemical stability through acetylation and exhibits antioxidant and moisturizing effects in this invention, while also reducing free radical damage. Sodium hyaluronate helps stimulate fibroblast proliferation, promotes collagen and angiogenesis, shortens the repair cycle, reduces wound exudate, and lowers the risk of infection. Chlorhexidine digluconate achieves a bactericidal effect, primarily adsorbing onto the bacterial cytoplasmic membrane permeability barrier, causing leakage of cell contents and exerting an antibacterial effect. At low concentrations, it inhibits bacterial growth, is gentle on skin and mucous membranes, and is non-allergenic.

[0020] Polyvinylpyrrolidone (PVP), as a film-forming agent, forms a transparent, non-occlusive polymeric film on the vulvar surface. This film adheres closely to the skin and mucous membranes, acting as a physical barrier to effectively isolate bacteria and contaminants while allowing gas exchange. Sodium alginate forms a soft gel upon contact with inflammatory exudate, locking in moisture and maintaining adequate hydration; it maintains a slightly acidic environment on the wound surface, inhibiting bacterial growth; the released calcium ions participate in coagulation, aiding hemostasis; and the polysaccharide components stimulate tissue repair. Polysorbate acts as a solubilizer in this invention, ensuring a relatively uniform and stable dispersion system for all components. Luteolin is a natural flavonoid compound widely found in plants such as chrysanthemum, honeysuckle, and perilla, possessing anti-inflammatory, antioxidant, antibacterial, and immunomodulatory effects. Quercetin reduces inflammatory responses by inhibiting the release of inflammatory factors such as TNF-α and IL-6, and by blocking inflammatory signaling pathways such as NF-κB and MAPK; it also has a direct inhibitory effect on microorganisms such as streptococci and Candida. Matrine has certain anti-inflammatory effects and interferes with HPV DNA synthesis, thereby achieving antiviral effects. At the same time, matrine has a good antibacterial effect against Staphylococcus aureus.

[0021] This invention provides an antibacterial dressing composition and a medical gynecological pad. The technical solution uses chitosan quaternary ammonium salt and chlorhexidine digluconate as bactericidal components, and adds quercetin and matrine as antibacterial agents. These are dispersed in a system with active ingredients such as panthenol, L-cysteine, tocopheryl acetate, sodium alginate, and luteolin, as well as film-forming agents such as polyvinylpyrrolidone and polyethylene glycol. This invention not only exhibits significant antibacterial properties but also possesses anti-inflammatory, moisturizing, and tissue-repair-promoting effects. Furthermore, the invention also contains carbomer and glycerin, which are beneficial for improving the condition of inflamed mucosal tissue and skin surface. Applying this dressing to the vulvar inflamed surface via a gynecological pad can achieve a definite therapeutic effect; moreover, this method of administration is convenient and comfortable. Attached Figure Description

[0022] Figure 1This is a statistical chart showing the diameter of the inhibition zones of the dressings in various embodiments and comparative examples of the present invention against Staphylococcus aureus, Candida albicans, and beta-hemolytic streptococci.

[0023] Figure 2 This is a statistical chart showing the minimum inhibitory concentrations (MICs) of the dressings used in various embodiments and comparative examples of the present invention against Staphylococcus aureus, Candida albicans, and beta-hemolytic streptococci.

[0024] Figure 3 This is a statistical chart showing the survival rate of Staphylococcus aureus, Candida albicans, and beta-hemolytic streptococci co-cultured with dressings from various embodiments and comparative examples in a specific embodiment of the present invention.

[0025] Figure 4 This is a statistical chart showing the therapeutic effects of various embodiments and comparative dressings on chronic bacterial vulvitis in specific implementations of the present invention. Detailed Implementation

[0026] The specific embodiments of the present invention will be described in detail below. To avoid excessive and unnecessary detail, well-known structures or functions will not be described in detail in the following embodiments. The approximate language used in the following embodiments is for quantitative purposes, indicating that a certain degree of variation in quantity is permissible without changing the basic function. Unless otherwise defined, the technical and scientific terms used in the following embodiments have the same meaning as commonly understood by those skilled in the art to which this invention pertains.

[0027] Example 1 An antibacterial dressing composition comprises the following components in parts by weight: 77 parts water, 9.8 parts polyethylene glycol, 4.3 parts glycerin, 0.48 parts carbomer, 0.09 parts L-cysteine, 4.5 parts chitosan quaternary ammonium salt, 0.6 parts panthenol, 0.5 parts tocopheryl acetate, 0.35 parts sodium hyaluronate, 0.18 parts chlorhexidine digluconate, 3.4 parts polyvinylpyrrolidone, 3.7 parts sodium alginate, 0.22 parts polysorbate, 0.73 parts luteolin, 0.16 parts quercetin, and 0.09 parts matrine.

[0028] Example 2 An antibacterial dressing composition comprises the following components in parts by weight: 85 parts water, 8.3 parts polyethylene glycol, 5 parts glycerin, 0.62 parts carbomer, 0.14 parts L-cysteine, 7.1 parts chitosan quaternary ammonium salt, 0.66 parts panthenol, 0.58 parts tocopheryl acetate, 0.25 parts sodium hyaluronate, 0.15 parts chlorhexidine digluconate, 3.8 parts polyvinylpyrrolidone, 2.9 parts sodium alginate, 0.17 parts polysorbate, 0.9 parts luteolin, 0.11 parts quercetin, and 0.16 parts matrine.

[0029] Example 3 An antibacterial dressing composition comprises the following components in parts by weight: 80 parts water, 9.1 parts polyethylene glycol, 4.8 parts glycerin, 0.53 parts carbomer, 0.11 parts L-cysteine, 6.2 parts chitosan quaternary ammonium salt, 0.55 parts panthenol, 0.62 parts tocopheryl acetate, 0.31 parts sodium hyaluronate, 0.29 parts chlorhexidine digluconate, 3.6 parts polyvinylpyrrolidone, 3.4 parts sodium alginate, 0.2 parts polysorbate, 0.82 parts luteolin, 0.15 parts quercetin, and 0.17 parts matrine.

[0030] Example 4 An antibacterial dressing composition comprises the following components in parts by weight: 80 parts water, 9.1 parts polyethylene glycol, 4.8 parts glycerin, 0.53 parts carbomer, 0.11 parts L-cysteine, 6.2 parts chitosan quaternary ammonium salt, 0.55 parts panthenol, 0.62 parts tocopheryl acetate, 0.31 parts sodium hyaluronate, 0.29 parts chlorhexidine digluconate, 3.6 parts polyvinylpyrrolidone, 3.4 parts sodium alginate, 0.2 parts polysorbate, 0.82 parts luteolin, 0.15 parts quercetin, 0.17 parts matrine, 1.1 parts xanthan gum, 0.06 parts epidermal growth factor (EGF), 0.13 parts silk fibroin, and 0.52 parts baicalin.

[0031] Comparative Example 1 "Yugongfang" brand medical gynecological liquid dressing is produced by Shanxi Health Road Medical Equipment Co., Ltd.

[0032] Comparative Example 2 "Bangfuke" brand gynecological liquid dressings are produced by Jiangxi Bangfuke Pharmaceutical Co., Ltd.

[0033] Experimental Example The Staphylococcus aureus bacterial suspension was evenly spread on the surface of the solid culture medium. Several non-woven fabric discs with a diameter of 8 mm were cut and sprayed with 0.1 mL / cm² water. 2 The liquid dressings of Examples 1-4 and Comparative Examples 1-2 were coated onto the surface of the nonwoven fabric discs, which were then placed on the culture medium. After incubation at 37°C for 24 hours, the diameter of the inhibition zone formed around the discs was measured. The diameter of the inhibition zone against Candida albicans and beta-hemolytic streptococci was determined using the same method.

[0034] Different concentrations of the liquid dressings from Examples 1-4 and Comparative Examples 1-2 were added to liquid culture media containing the same concentration of Staphylococcus aureus bacterial suspension and cultured with shaking at 37°C for 24 hours. A culture system with an absorbance OD600 less than 0.1 was designated as the inhibition group, and the lowest concentration of each liquid dressing in the inhibition group was the minimum inhibitory concentration (MIC). The MIC of each liquid dressing against Candida albicans and beta-hemolytic streptococci was determined using the same method.

[0035] Liquid dressings from Examples 1-4 and Comparative Examples 1-2 were added to Staphylococcus aureus bacterial suspension at a volume ratio of 0.5%, and co-cultured for 24 hours. Appropriate amounts of the bacterial suspension were then serially diluted, and the diluted suspensions were spread onto solid culture media and incubated at 37°C for 24 hours. The number of colonies formed on the culture media was counted and compared with the number of colonies in the control group (not co-cultured with the dressings) to calculate the bacterial survival rate. Bacterial survival rate = (number of colonies in experimental group / number of colonies in control group) × 100%.

[0036] The experimental results showed that for Staphylococcus aureus, the inhibition zone diameter of the dressing in Example 1 was 21 mm, the inhibition zone diameter of the dressing in Example 2 was 20 mm, the inhibition zone diameter of the dressing in Example 3 was 21 mm, and the inhibition zone diameter of the dressing in Example 4 was 23 mm; the inhibition zone diameter of the dressing in Comparative Example 1 was 12 mm, and the inhibition zone diameter of the dressing in Comparative Example 2 was 10 mm. For Candida albicans, the inhibition zone diameter of the dressing in Example 1 was 17 mm, the inhibition zone diameter of the dressing in Example 2 was 18 mm, the inhibition zone diameter of the dressing in Example 3 was 19 mm, the inhibition zone diameter of the dressing in Example 4 was 20 mm, the inhibition zone diameter of the dressing in Comparative Example 1 was 10 mm, and the inhibition zone diameter of the dressing in Comparative Example 2 was less than 9 mm. For beta-hemolytic streptococci, the diameter of the inhibition zone of the dressing in Example 1 was 20 mm, the diameter of the inhibition zone of the dressing in Example 2 was 17 mm, the diameter of the inhibition zone of the dressing in Example 3 was 18 mm, the diameter of the inhibition zone of the dressing in Example 4 was 20 mm, the diameter of the inhibition zone of the dressing in Comparative Example 1 was 9 mm, and no inhibition zone was observed in the dressing in Comparative Example 2.

[0037] For Staphylococcus aureus, the minimum inhibitory concentration (MIC) of the dressing in Example 1 was 1.5 mL / L, the MIC of the dressing in Example 2 was 1.5 mL / L, the MIC of the dressing in Example 3 was 1.5 mL / L, the MIC of the dressing in Example 4 was 1 mL / L, the MIC of the dressing in Comparative Example 1 was 5 mL / L, and the MIC of the dressing in Comparative Example 2 was 6.5 mL / L. For Candida albicans, the MIC of the dressing in Example 1 was 2 mL / L, the MIC of the dressing in Example 2 was 2 mL / L, the MIC of the dressing in Example 3 was 2.5 mL / L, the MIC of the dressing in Example 4 was 1.5 mL / L, the MIC of the dressing in Comparative Example 1 was 8.5 mL / L, and the MIC of the dressing in Comparative Example 2 was not determined (greater than 10 mL / L). For beta-hemolytic streptococci, the minimum inhibitory concentration (MIC) of the dressing in Example 1 was 1.5 mL / L, the MIC of the dressing in Example 2 was 2 mL / L, the MIC of the dressing in Example 3 was 1.5 mL / L, the MIC of the dressing in Example 4 was 1.5 mL / L, the MIC of the dressing in Comparative Example 1 was not determined (greater than 10 mL / L), and the MIC of the dressing in Comparative Example 2 was not determined (greater than 10 mL / L).

[0038] For Staphylococcus aureus, the survival rate was 2.4% when co-cultured with the dressing of Example 1, 2.9% when co-cultured with the dressing of Example 2, 3.3% when co-cultured with the dressing of Example 3, 1.8% when co-cultured with the dressing of Example 4, 9.9% when co-cultured with the dressing of Comparative Example 1, and 21.7% when co-cultured with the dressing of Comparative Example 2. For Candida albicans, the survival rate was 4.0% when co-cultured with the dressing of Example 1, 3.5% when co-cultured with the dressing of Example 2, 6.2% when co-cultured with the dressing of Example 3, 3.8% when co-cultured with the dressing of Example 4, 41.4% when co-cultured with the dressing of Comparative Example 1, and 62.7% when co-cultured with the dressing of Comparative Example 2. For beta-hemolytic streptococci, the survival rate was 3.3% when co-cultured with the dressing of Example 1, 3.9% when co-cultured with the dressing of Example 2, 2.7% when co-cultured with the dressing of Example 3, 2.5% when co-cultured with the dressing of Example 4, 68.3% when co-cultured with the dressing of Comparative Example 1, and 76.4% when co-cultured with the dressing of Comparative Example 1.

[0039] Sixty patients with chronic bacterial vulvitis were randomly divided into six groups of 10 each. Each group used the liquid dressings from Examples 1-4 and Comparative Examples 1-2 for 3 weeks. The administration method was as follows: "Seven Degrees Space" brand "Girls' Panty Liners" produced by Fujian Heng'an Group Co., Ltd. were purchased. First, 0.5 mL of the liquid dressing was evenly sprayed onto the patient's vulva, and then 0.1 mL / cm² was applied to the skin surface of the panty liner. 2 Apply the liquid dressing by spraying the correct amount, then attach the pad to the vulva; change every 12 hours.

[0040] The efficacy was assessed after 3 weeks. The results showed that: the effective rate of the dressing in Example 1 was 100%, and the cure rate reached 60%; the effective rate of the dressing in Example 2 was 100%, and the cure rate reached 40%; the effective rate of the dressing in Example 3 was 100%, and the cure rate reached 50%; the effective rate of the dressing in Example 4 was 100%, and the cure rate reached 70%; the effective rate of the dressing in Comparative Example 1 was 50%, and the cure rate was 0; the effective rate of the dressing in Comparative Example 2 was 30%, and the cure rate was 0.

[0041] The embodiments of the present invention have been described in detail above, but the content described is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, and improvements made within the scope of the present invention should be included within the protection scope of the present invention.

Claims

1. An antibacterial dressing composition, characterized in that... The product comprises the following components by weight: 70-90 parts water, 8-10 parts polyethylene glycol, 4-6 parts glycerin, 0.3-0.7 parts carbomer, 0.06-0.15 parts L-cysteine, 4-8 parts chitosan quaternary ammonium salt, 0.3-0.8 parts panthenol, 0.4-0.7 parts tocopheryl acetate, 0.2-0.4 parts sodium hyaluronate, 0.1-0.3 parts chlorhexidine digluconate, 3-4 parts polyvinylpyrrolidone, 1-5 parts sodium alginate, 0.1-0.3 parts polysorbate, 0.6-0.9 parts luteolin, 0.1-0.2 parts quercetin, and 0.05-0.2 parts matrine.

2. The antibacterial dressing composition according to claim 1, characterized in that, The antibacterial dressing composition also includes 0.8 to 1.7 parts by weight of xanthan gum.

3. The antibacterial dressing composition according to claim 1, characterized in that, The antibacterial dressing composition also includes 0.03 to 0.08 parts by weight of epidermal growth factor (EGF).

4. The antibacterial dressing composition according to claim 1, characterized in that, The antibacterial dressing composition also includes 0.06 to 0.15 parts by weight of silk fibroin.

5. The antibacterial dressing composition according to claim 1, characterized in that, The antibacterial dressing composition also includes 0.5 to 0.8 parts by weight of baicalin.

6. The antibacterial dressing composition according to claim 1, characterized in that, The antibacterial dressing composition comprises the following components in parts by weight: 75-85 parts water, 8.8-9.4 parts polyethylene glycol, 4.5-5 parts glycerin, 0.4-0.6 parts carbomer, 0.08-0.12 parts L-cysteine, 5-7 parts chitosan quaternary ammonium salt, 0.4-0.6 parts panthenol, 0.5-0.65 parts tocopheryl acetate, 0.26-0.33 parts sodium hyaluronate, 0.25-0.3 parts chlorhexidine digluconate, 3.4-3.7 parts polyvinylpyrrolidone, 2.2-3.9 parts sodium alginate, 0.15-0.24 parts polysorbate, 0.8-0.85 parts luteolin, 0.12-0.16 parts quercetin, and 0.13-0.17 parts matrine.

7. The antibacterial dressing composition according to claim 6, characterized in that, This antibacterial dressing composition comprises the following components in parts by weight: 80 parts water, 9.1 parts polyethylene glycol, 4.8 parts glycerin, 0.53 parts carbomer, 0.11 parts L-cysteine, 6.2 parts chitosan quaternary ammonium salt, 0.55 parts panthenol, 0.62 parts tocopheryl acetate, 0.31 parts sodium hyaluronate, 0.29 parts chlorhexidine digluconate, 3.6 parts polyvinylpyrrolidone, 3.4 parts sodium alginate, 0.2 parts polysorbate, 0.82 parts luteolin, 0.15 parts quercetin, and 0.17 parts matrine.

8. The antibacterial dressing composition according to claim 6, characterized in that, This antibacterial dressing composition comprises the following components in parts by weight: 80 parts water, 9.1 parts polyethylene glycol, 4.8 parts glycerin, 0.53 parts carbomer, 0.11 parts L-cysteine, 6.2 parts chitosan quaternary ammonium salt, 0.55 parts panthenol, 0.62 parts tocopheryl acetate, 0.31 parts sodium hyaluronate, 0.29 parts chlorhexidine digluconate, 3.6 parts polyvinylpyrrolidone, 3.4 parts sodium alginate, 0.2 parts polysorbate, 0.82 parts luteolin, 0.15 parts quercetin, 0.17 parts matrine, 1.1 parts xanthan gum, 0.06 parts epidermal growth factor (EGF), 0.13 parts silk fibroin, and 0.52 parts baicalin.

9. A medical gynecological pad containing the antibacterial dressing composition according to any one of claims 1 to 8.

10. The medical gynecological pad according to claim 9, characterized in that, The antibacterial dressing composition is sprayed onto the contact surface of the medical gynecological pad that comes into contact with the human body.

Images